专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

US20120251523A1 Methods of Modulating TGFbeta Signaling 有权
标题翻译：调节TGFbeta信号传导的方法
公开(公告)号：US20120251523A1
公开(公告)日：2012-10-04
申请号：US13355798
申请日：2012-01-23
申请人： Derya Unutmaz , Aimee El Hed
发明人： Derya Unutmaz , Aimee El Hed
IPC分类号： A61K39/395 , C12Q1/06 , A61P37/06 , A61K31/7088 , A61K38/48 , C12Q1/04 , G01N33/573
CPC分类号： G01N33/56972 , A61K38/4886 , C12Y304/24046 , G01N2333/495
摘要： The present invention provides methods of identifying the presence of or quantifying the amount of one or more of T helper (Th) cells and iTreg cells present in a sample by identifying the presence of an ADAM or the amount of an ADAM, such as ADAM12, present in a sample. The present invention also provides methods for increasing or decreasing signaling of a TGF such as TGFβ by increasing or decreasing the biological activity or expression of an ADAM. Further, the present invention provides methods for inhibiting or stimulating, downregulating or upregulating, an immune response, and for treating diseases associated with an immune response such as cancer, viral, bacterial and fungal infections, autoimmune diseases and graft versus host diseases. Still further, the invention provides screening methods effective for identifying therapeutic agents, pharmaceutical compositions containing therapeutic agents, and vaccines.
摘要翻译：本发明提供通过鉴定ADAM的存在或ADAM的量（例如ADAM12）鉴定存在于样品中的T辅助细胞（Th）细胞和iTreg细胞中的一种或多种的量的存在或定量的方法，存在于样品中。本发明还提供了用于增加或减少TGF的信号传递的方法，例如TGFβb; 通过增加或减少ADAM的生物活性或表达。此外，本发明提供了用于抑制或刺激，下调或上调免疫应答以及用于治疗与诸如癌症，病毒，细菌和真菌感染，自身免疫性疾病和移植物抗宿主病等免疫应答相关的疾病的方法。此外，本发明提供了有效地鉴定治疗剂，含有治疗剂的药物组合物和疫苗的筛选方法。

2. 发明授权

US08846609B2 Leukotoxin E/D as a new anti-inflammatory agent and microbicide 有权
标题翻译：白介素E / D作为新型抗炎剂和杀微生物剂
公开(公告)号：US08846609B2
公开(公告)日：2014-09-30
申请号：US13527438
申请日：2012-06-19
申请人： Victor J. Torres , Derya Unutmaz , Francis Alonzo, III
发明人： Victor J. Torres , Derya Unutmaz , Francis Alonzo, III
IPC分类号： A01N37/18 , A61K38/04 , A61P31/12 , A01N43/42 , A61K31/44 , A61K31/497 , A61K39/395 , A61K38/16
CPC分类号： A61K38/164 , A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K9/0053 , A61K31/351 , A61K31/439 , A61K31/46 , A61K31/506 , A61K39/3955 , A61K45/06 , C07K16/2866 , C07K16/2896 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.
摘要翻译：本发明涉及在受试者中预防或治疗人类免疫缺陷病毒（HIV）感染，炎性病症和移植物抗宿主病（GVHD）的方法。本发明的治疗组合物包含白念珠菌素E（LukE）和/或D蛋白或多肽。本发明还涉及通过施用包含CCR5拮抗剂或阻断与CCR5 +细胞的LukE / D相互作用的组合物的组合物以有效治疗受试者的金黄色葡萄球菌感染的量来治疗金黄色葡萄球菌感染的方法。

3. 发明申请

US20130039885A1 LEUKOTOXIN E/D AS A NEW ANTI-INFLAMMATORY AGENT AND MICROBICIDE 有权
公开(公告)号：US20130039885A1
公开(公告)日：2013-02-14
申请号：US13527438
申请日：2012-06-19
申请人： Victor J. TORRES , Derya UNUTMAZ , Francis ALONZO, III
发明人： Victor J. TORRES , Derya UNUTMAZ , Francis ALONZO, III
IPC分类号： A61K38/16 , A61P31/18 , A61P29/00 , A61P19/02 , A61P17/06 , A61P9/10 , A61P1/00 , A61P1/04 , A61P25/00 , A61P3/10 , A61P1/16 , A61P19/04 , A61P31/06 , A61P31/00 , A61P19/08 , A61P37/06 , A61K31/46 , A61P31/04 , A61K31/506 , A61K39/395 , A61K31/351 , A61K38/20
CPC分类号： A61K38/164 , A61K9/0014 , A61K9/0031 , A61K9/0034 , A61K9/0053 , A61K31/351 , A61K31/439 , A61K31/46 , A61K31/506 , A61K39/3955 , A61K45/06 , C07K16/2866 , C07K16/2896 , C07K2317/76 , A61K2300/00
摘要： The present invention relates to methods for preventing or treating Human Immunodeficiency Virus (HIV) infection, inflammatory conditions, and graft-versus-host-disease (GVHD) in a subject. Therapeutic compositions of the present invention comprise Leukocidin E (LukE) and/or D proteins or polypeptides. The invention further relates to methods of treating Staphylococcus aureus infection by administering a composition comprising a CCR5 antagonist or any molecule that blocks LukE/D interaction with CCR5+ cells in an amount effective to treat the S. aureus infection in the subject.

4. 发明授权

US08992933B2 Methods for activating T cells and modulating an immune response 有权
标题翻译：激活T细胞和调节免疫反应的方法
公开(公告)号：US08992933B2
公开(公告)日：2015-03-31
申请号：US13548277
申请日：2012-07-13
申请人： Derya Unutmaz , Qi Wan , Lina Kozhaya
发明人： Derya Unutmaz , Qi Wan , Lina Kozhaya
IPC分类号： A61K39/00 , C07K14/435
CPC分类号： A61K39/0008
摘要： The present invention is directed to a method for promoting differentiation, activation and proliferation of human T helper lymphocytes such as those that express IL17 and IL22 (Th-IL17+ and Th-IL22+ T cells) and provides methods for decreasing T cell activation or T cell biological activity, inhibiting an immune response and treating autoimmune diseases by increasing the biological activity of or administering a transcription factor such as a Krüppel-like factor or a forkhead box factor, and pharmaceutical compositions effective for these methods. Also, the present invention provides methods for increasing T cell activation or T cell biological activity, stimulating an immune response and treating diseases such as cancers and infections by decreasing the biological activity of or administering an inhibitor of a transcription factor such as a Krüppel-like factor or a forkhead box factor and pharmaceutical compositions effective for these methods.
摘要翻译：本发明涉及促进人T辅助淋巴细胞的分化，活化和增殖的方法，例如表达IL17和IL22（Th-IL17 +和Th-IL22 + T细胞）的那些，并提供降低T细胞活化或T细胞的方法生物活性，抑制免疫应答和通过增加转录因子如Krüppel样因子或叉头盒因子的生物学活性和治疗自身免疫疾病，以及对这些方法有效的药物组合物。此外，本发明提供了增加T细胞活化或T细胞生物活性，刺激免疫应答并通过降低转录因子如Krüppel样的抑制剂的生物活性或治疗疾病如癌症和感染的方法因子或叉头盒因子和对这些方法有效的药物组合物。

5. 发明申请

US20130045491A1 METHODS FOR ACTIVATING T CELLS 审中-公开
标题翻译：激活T细胞的方法
公开(公告)号：US20130045491A1
公开(公告)日：2013-02-21
申请号：US13551707
申请日：2012-07-18
申请人： Derya Unutmaz
发明人： Derya Unutmaz
IPC分类号： C12N5/0783 , G01N33/53
CPC分类号： C12N5/0636 , C12N2501/51 , C12N2501/515 , C12N2510/00
摘要： The present invention is directed to a method for promoting function, activation and proliferation of T helper lymphocytes such as those that express IL17 and IL22 (Th-IL17+ and Th-IL22+ T cells). The method features isolating a population of T cells from a subject such as a human and incubating the population of T cells in a serum-free culture medium that contains one or more cytokine. The T cells may be memory T cells (TM) such as, for example, CCR6+CD45RO+ memory T cells (TM), and the one or more cytokine may be, for instance, one or more of IL-2, IL-7 and IL-15. Likewise, the invention provides a method for expanding an activated population of T helper lymphocytes by the same means.
摘要翻译：本发明涉及促进T辅助淋巴细胞的功能，活化和增殖的方法，例如表达IL17和IL22（Th-IL17 +和Th-IL22 + T细胞）的那些。该方法的特征是从受试者如人中分离出一组T细胞，并在含有一种或多种细胞因子的无血清培养基中孵育T细胞群。 T细胞可以是记忆T细胞TM，例如CCR6 + CD45RO +记忆T细胞TM，并且一种或多种细胞因子可以是例如IL-2，IL-7中的一种或多种和IL-15。同样地，本发明提供了一种通过相同的方法来扩增活化的T辅助淋巴细胞群的方法。

6. 发明授权

US08703128B2 Methods of modulating TGFβ signaling 有权
标题翻译： TGF-bgr调节方法信令
公开(公告)号：US08703128B2
公开(公告)日：2014-04-22
申请号：US13355798
申请日：2012-01-23
申请人： Derya Unutmaz , Aimee El Hed
发明人： Derya Unutmaz , Aimee El Hed
IPC分类号： A61K39/395 , C12N15/11 , A61K38/46 , G01N33/573
CPC分类号： G01N33/56972 , A61K38/4886 , C12Y304/24046 , G01N2333/495
摘要： The present invention provides methods of identifying the presence of or quantifying the amount of one or more of T helper (Th) cells and iTreg cells present in a sample by identifying the presence of an ADAM or the amount of an ADAM, such as ADAM12, present in a sample. The present invention also provides methods for increasing or decreasing signaling of a TGF such as TGFβ by increasing or decreasing the biological activity or expression of an ADAM. Further, the present invention provides methods for inhibiting or stimulating, downregulating or upregulating, an immune response, and for treating diseases associated with an immune response such as cancer, viral, bacterial and fungal infections, autoimmune diseases and graft versus host diseases. Still further, the invention provides screening methods effective for identifying therapeutic agents, pharmaceutical compositions containing therapeutic agents, and vaccines.
摘要翻译：本发明提供通过鉴定ADAM的存在或ADAM的量（例如ADAM12）鉴定存在于样品中的T辅助细胞（Th）细胞和iTreg细胞中的一种或多种的量的存在或定量的方法，存在于样品中。本发明还提供了用于增加或减少TGF的信号传递的方法，例如TGFβb; 通过增加或减少ADAM的生物活性或表达。此外，本发明提供了用于抑制或刺激，下调或上调免疫应答以及用于治疗与诸如癌症，病毒，细菌和真菌感染，自身免疫性疾病和移植物抗宿主病等免疫应答相关的疾病的方法。此外，本发明提供了有效地鉴定治疗剂，含有治疗剂的药物组合物和疫苗的筛选方法。

7. 发明申请

US20110200573A1 Methods of inhibiting retrovirus replication and infectivity 审中-公开
标题翻译：抑制逆转录病毒复制和感染的方法
公开(公告)号：US20110200573A1
公开(公告)日：2011-08-18
申请号：US12931608
申请日：2011-02-04
申请人： Derya Unutmaz , Vyacheslav Furtak
发明人： Derya Unutmaz , Vyacheslav Furtak
IPC分类号： A61K38/43 , C12N9/00 , A61P31/18 , C40B30/00
CPC分类号： A61K38/162
摘要： The present invention provides methods of inhibiting a retrovirus replication or infectivity by administering a therapeutically effective amount of MOV10 or a fragment, derivative or analog thereof or an inhibitor of MOV10 or a fragment, derivative or analog thereof or of inhibiting a retrovirus replication or infectivity by increasing or decreasing transcription, translation or biological activity of MOV10 or a fragment, derivative or analog thereof. In some instances the retrovirus is HIV or HIV-1. The present invention also features methods of treating a disease caused all or in part by a retrovirus, such as HIV or HIV-1, by administering a therapeutically effective amount of MOV10 or a fragment, derivative or analog thereof or an inhibitor thereof or by increasing or decreasing transcription, translation or biological activity of MOV10 or a fragment, derivative or analog thereof. Further, the present invention features methods to identify an agent that may inhibit a retrovirus comprising identifying an agent that is regulated by MOV10 or a fragment, derivative or analog thereof.
摘要翻译：本发明提供了通过施用治疗有效量的MOV10或其片段，衍生物或类似物或其片段，衍生物或类似物或其片段，衍生物或类似物或抑制逆转录病毒复制或感染性的方法来抑制逆转录病毒复制或感染性的方法增加或减少MOV10或其片段，衍生物或类似物的转录，翻译或生物活性。在某些情况下，逆转录病毒是HIV或HIV-1。本发明还涉及通过施用治疗有效量的MOV10或其片段，衍生物或类似物或其抑制剂或通过增加或增加抗体来治疗由全部或部分由逆转录病毒例如HIV或HIV-1引起的疾病的疾病的方法或降低MOV10或其片段，衍生物或类似物的转录，翻译或生物活性。此外，本发明的特征在于鉴定可能抑制逆转录病毒的试剂的方法，包括鉴定由MOV10调节的试剂或其片段，衍生物或类似物。

8. 发明授权

US06696244B2 G-coupled receptors associated with retroviral entry into cells, and therapeutic uses thereof 有权
标题翻译：与逆转录病毒进入细胞相关的G偶联受体及其治疗用途
公开(公告)号：US06696244B2
公开(公告)日：2004-02-24
申请号：US09852156
申请日：2001-05-09
申请人： Dan R. Littman , Hongkui Deng , Derya Unutmaz , Vineet N. Kewalramani
发明人： Dan R. Littman , Hongkui Deng , Derya Unutmaz , Vineet N. Kewalramani
IPC分类号： C12Q170
CPC分类号： G01N33/56988 , A01K67/0275 , A01K2217/072 , A01K2267/0393 , A61K39/39 , C07K14/7158 , C07K16/2866 , C12N2740/16043 , C12N2810/6054 , G01N33/74 , G01N2333/726
摘要： The present invention provides two new HIV/SIV translocation promoting agents, Bonzo and BOB. The present invention also provides the amino acid and DNA sequences of human, African green monkey, and pigtail macaque of the receptor protein Bonzo. Mammalian cells transfected with Bonzo and/or BOB and human CD4 as well as antibodies to the receptor Bonzo are also included. Furthermore, a method of identifying other such translocation promoting agents is also disclosed. Diagnostic and therapeutic uses of the translocation promoting agents of the present invention are also provided. Furthermore, the present invention provides methods of identifying agents that can modulate the expression and/or function of Bonzo/STRL33. Such agents can be used to either treat inflamation, or alternatively, to enhance the immune response.
摘要翻译：本发明提供两种新的HIV / SIV易位促进剂Bonzo和BOB。本发明还提供了受体蛋白质Bonzo的人，非洲绿猴和猪尾猕猴的氨基酸和DNA序列。还包括用Bonzo和/或BOB和人CD4转染的哺乳动物细胞以及受体Bonzo的抗体。此外，还公开了鉴定其他这种易位促进剂的方法。还提供了本发明的易位促进剂的诊断和治疗用途。此外，本发明提供鉴定可以调节Bonzo / STRL33的表达和/或功能的试剂的方法。这种药剂可用于治疗炎症，或者替代地增强免疫应答。

9. 发明申请

US20130058964A1 METHODS FOR ACTIVATING T CELLS AND MODULATING AN IMMUNE RESPONSE 有权
标题翻译：用于激活T细胞和调节免疫应答的方法
公开(公告)号：US20130058964A1
公开(公告)日：2013-03-07
申请号：US13548277
申请日：2012-07-13
申请人： Derya Unutmaz , Qi Wan , Lina Kozhaya
发明人： Derya Unutmaz , Qi Wan , Lina Kozhaya
IPC分类号： A61K39/00 , A61P35/00 , A61P31/04 , A61P31/12 , A61P37/06 , A61P37/04
CPC分类号： A61K39/0008
摘要： The present invention is directed to a method for promoting differentiation, activation and proliferation of human T helper lymphocytes such as those that express IL17 and IL22 (Th-IL17+ and Th-IL22+ T cells) and provides methods for decreasing T cell activation or T cell biological activity, inhibiting an immune response and treating autoimmune diseases by increasing the biological activity of or administering a transcription factor such as a Krüppel-like factor or a forkhead box factor, and pharmaceutical compositions effective for these methods. Also, the present invention provides methods for increasing T cell activation or T cell biological activity, stimulating an immune response and treating diseases such as cancers and infections by decreasing the biological activity of or administering an inhibitor of a transcription factor such as a Krüppel-like factor or a forkhead box factor and pharmaceutical compositions effective for these methods.
摘要翻译：本发明涉及促进人T辅助淋巴细胞的分化，活化和增殖的方法，例如表达IL17和IL22（Th-IL17 +和Th-IL22 + T细胞）的那些，并提供降低T细胞活化或T细胞的方法生物活性，抑制免疫应答和通过增加转录因子如Krüppel样因子或叉头盒因子的生物学活性和治疗自身免疫疾病，以及对这些方法有效的药物组合物。此外，本发明提供了增加T细胞活化或T细胞生物活性，刺激免疫应答并通过降低转录因子如Krüppel样的抑制剂的生物活性或治疗疾病如癌症和感染的方法因子或叉头盒因子和对这些方法有效的药物组合物。

10. 发明申请

US20070191322A1 Cationic Steroid Microbial Compositions and Methods of Use 审中-公开
标题翻译：阳离子类固醇微生物组合物和使用方法
公开(公告)号：US20070191322A1
公开(公告)日：2007-08-16
申请号：US11669854
申请日：2007-01-31
申请人： Paul Savage , Peter Wright , Derya Unutmaz
发明人： Paul Savage , Peter Wright , Derya Unutmaz
IPC分类号： A61K31/56 , C12Q1/70
CPC分类号： A61K31/56 , A61K31/568 , A61K31/57 , A61K31/575 , A61K45/06 , A61K2300/00
摘要： The invention relates to methods for decreasing or inhibiting influenza virus infection or pathogenesis of a cell in vitro, ex vivo or in vivo, a symptom or pathology associated with influenza infection or pathogenesis in vitro, ex vivo or in vivo, or an adverse side effect of influenza infection or pathogenesis in vitro, ex vivo or in vivo. In one embodiment, a method of the invention includes treating a subject with an invention compound (e.g., cationic steroid antimicrobial or CSA).
摘要翻译：本发明涉及在体外，体内或体内降低或抑制流感病毒感染或细胞发病的方法，体外或离体或体内与流感感染或发病相关的症状或病理学或不良副作用的流感感染或发病机制，离体或体内。在一个实施方案中，本发明的方法包括用本发明化合物（例如阳离子类固醇抗微生物剂或CSA）治疗受试者。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式